Philadelphia, United States
BioPhy, founded in 2020, is at the forefront of transforming the pharmaceutical sector through its strategic use of AI. Positioned at the intersection of AI, Biotechnology, and Health Care, the company offers cutting-edge solutions tailored to enhance drug development processes. With a clear focus on addressing critical challenges in quality, compliance, manufacturing, and supply-chain operations, BioPhy's industry-specific AI transforms operations into more efficient and intelligent processes.
Headquartered in the United States, BioPhy has attracted significant investor interest. Notably, the company secured a $4.50M Pre Seed Round investment on 07 November 2023 with backers such as Metrodora Ventures, Audere Capital, TRCM Fund, and industry figure Jeffrey Marrazzo. This infusion of capital underscores the confidence in BioPhy's potential to revolutionize pharmaceutical operations, making it a compelling opportunity for further investment.
